Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Hancock Whitney Corp

Hancock Whitney Corp lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,356 shares of the medical research company’s stock after selling 45 shares during the period. Hancock Whitney Corp’s holdings in Thermo Fisher Scientific were worth $3,313,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Waverly Advisors LLC raised its position in Thermo Fisher Scientific by 7.1% during the first quarter. Waverly Advisors LLC now owns 2,386 shares of the medical research company’s stock worth $1,387,000 after acquiring an additional 158 shares during the period. Tidal Investments LLC boosted its holdings in Thermo Fisher Scientific by 13.4% in the 1st quarter. Tidal Investments LLC now owns 16,728 shares of the medical research company’s stock worth $9,718,000 after buying an additional 1,972 shares during the last quarter. Beacon Capital Management LLC increased its stake in Thermo Fisher Scientific by 39.4% during the 1st quarter. Beacon Capital Management LLC now owns 198 shares of the medical research company’s stock worth $115,000 after buying an additional 56 shares in the last quarter. Brown Shipley& Co Ltd lifted its position in shares of Thermo Fisher Scientific by 11.8% in the first quarter. Brown Shipley& Co Ltd now owns 16,025 shares of the medical research company’s stock valued at $9,254,000 after acquiring an additional 1,685 shares in the last quarter. Finally, WealthPlan Investment Management LLC raised its stake in Thermo Fisher Scientific by 16.6% in the 1st quarter. WealthPlan Investment Management LLC now owns 2,629 shares of the medical research company’s stock valued at $1,528,000 after purchasing an additional 374 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 9,000 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $552.86, for a total value of $4,975,740.00. Following the sale, the chief executive officer now owns 14,608 shares of the company’s stock, valued at $8,076,178.88. This represents a 38.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the transaction, the executive vice president now owns 16,663 shares of the company’s stock, valued at $9,333,946.08. This represents a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 37,150 shares of company stock valued at $20,651,865 in the last 90 days. 0.34% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have issued reports on TMO. Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a research note on Friday, September 20th. Stephens assumed coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, October 1st. They set an “overweight” rating and a $680.00 price objective for the company. Bank of America boosted their target price on Thermo Fisher Scientific from $600.00 to $675.00 and gave the stock a “buy” rating in a report on Monday, September 16th. Stifel Nicolaus reduced their price objective on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. Finally, Redburn Atlantic began coverage on Thermo Fisher Scientific in a research note on Monday, October 14th. They issued a “buy” rating and a $680.00 target price for the company. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $649.33.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $514.05 on Tuesday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. Thermo Fisher Scientific Inc. has a one year low of $480.57 and a one year high of $627.88. The company’s fifty day moving average is $573.70 and its two-hundred day moving average is $579.75. The firm has a market capitalization of $196.62 billion, a P/E ratio of 32.23, a PEG ratio of 3.39 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm’s quarterly revenue was up .2% compared to the same quarter last year. During the same period last year, the company posted $5.69 earnings per share. Analysts forecast that Thermo Fisher Scientific Inc. will post 21.67 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its board has approved a stock buyback program on Friday, November 15th that permits the company to repurchase $4.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.30%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.